Levitra

Vardenafil, the active ingredient in Levitra, is a phosphodiesterase type 5 (PDE5) inhibitor presented as an oral tablet for oral use. It is prescribed to treat erectile dysfunction in adult males by improving penile blood flow during sexual stimulation. The drug is absorbed quickly, reaching peak levels within about an hour, and its effect can last up to 12 hours, offering a flexible window for activity.

GNH USA supplies Levitra as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levitra, a PDE5 inhibitor, is used to manage conditions related to impaired erectile function.

- Erectile dysfunction: improves ability to achieve and maintain an erection sufficient for sexual activity. - Psychogenic erectile dysfunction: enhances erectile response when the cause is psychological. - Erectile dysfunction associated with diabetes: increases penile blood flow to counteract vascular complications.

Vardenafil may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache - Flushing - Nasal congestion - Dyspepsia - Dizziness

Serious or Rare Side Effects: - Priapism (prolonged erection lasting >4 hours) - Sudden loss of vision (non‑arteritic anterior ischemic optic neuropathy) - Sudden loss of hearing - Cardiovascular events such as myocardial infarction or stroke (rare)

Before prescribing Levitra, clinicians should evaluate the following safety considerations.

- Cardiovascular assessment: confirm patient can tolerate sexual activity without undue risk. - Nitrate use: contraindicated with any nitrate medication due to risk of severe hypotension. - Alpha‑blocker therapy: use with caution and consider dose adjustment. - Alcohol consumption: advise limiting alcohol as it may enhance hypotensive effects. - Concomitant medications: review for potential CYP3A4 interactions. - Store at ambient temperature below 25°C: keep in original packaging, protect from moisture.

Levitra can interact with several drug classes; some combinations must be avoided while others require monitoring.

Major Interactions (Avoid): - Nitrates (e.g., nitroglycerin, isosorbide dinitrate): may cause life‑threatening hypotension. - Guanylate cyclase stimulators (e.g., riociguat): risk of severe blood pressure drop. - Other PDE5 inhibitors (e.g., sildenafil, tadalafil): additive effect on cGMP. - Protease inhibitors (e.g., ritonavir): increase vardenafil plasma levels. - Alpha‑adrenergic blockers (e.g., prazosin) at high doses: may cause marked hypotension.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise vardenafil exposure. - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce effectiveness. - Antihypertensive agents (e.g., beta‑blockers, ACE inhibitors): monitor blood pressure. - Diuretics: watch for additive hypotensive effect. - Antidepressants (e.g., SSRIs): may affect sexual function and require assessment.